Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	**PharmAust Limited**
ABN	**35 094 006 023**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Roger Aston
Date of last notice	14 August 2013

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	19 May 2014
No. of securities held prior to change	104,282,951 Fully Paid Ordinary Shares 528,634 Listed Options (ASX:PAAO)
Class	Ordinary Fully Paid Shares
Number acquired	500,000 Ordinary Fully Paid Shares
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$5,500.00
No. of securities held after change	104,782,951 Ordinary Fully Paid Shares 528,634 Listed Options (ASX:PAAO)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market trade

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	Milestone Shares The milestones for the issue of Shares under Resolution 4 approved by shareholders at the General Meeting on 5 August 2013: Milestone 1 - One of the Pitney Products being granted investigational new drug (IND) status from the US Food and Drug Administration and Pitney receiving an IND number issued by the US Food and Drug Administration within 5 years of the date of settlement of the Pitney Transaction. Milestone 2 - Commencement of treatment of the first patient under a Phase II Trial with the product Albendazole within 5 years of the date of settlement of the Pitney Transaction. Milestone 3 - Commencement of treatment of the first patient under a Phase II Trial using the product Monepantel within 5 years of the date of settlement of the Pitney Transaction.

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	**PharmAust Limited**
ABN	**35 094 006 023**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Robert Charles Bishop
Date of last notice	29 November 2013

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	The securities are held by Longbow Croft Capital Pty Ltd. Mr Bishop is the sole shareholder and director of Longbow Croft Capital Pty Ltd.
Date of change	19 & 20 May 2014
No. of securities held prior to change	53,071,824 Ordinary Fully Paid Shares 1,365,707 Listed Options (ASX:PAAO)
Class	Ordinary Fully Paid Shares
Number acquired	500,000 Ordinary Fully Paid Shares
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$5,200.00
No. of securities held after change	53,571,824 Ordinary Fully Paid Shares 1,365,707 Listed Options (ASX:PAAO)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market trade

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	Milestone Shares The milestones for the issue of Shares under Resolution 4 approved by shareholders at the General Meeting on 5 August 2013: Milestone 1 - One of the Pitney Products being granted investigational new drug (IND) status from the US Food and Drug Administration and Pitney receiving an IND number issued by the US Food and Drug Administration within 5 years of the date of settlement of the Pitney Transaction. Milestone 2 - Commencement of treatment of the first patient under a Phase II Trial with the product Albendazole within 5 years of the date of settlement of the Pitney Transaction. Milestone 3 - Commencement of treatment of the first patient under a Phase II Trial using the product Monepantel within 5 years of the date of settlement of the Pitney Transaction.

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	**PharmAust Limited**
ABN	**35 094 006 023**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Sam Michael Wright
Date of last notice	18 September 2013

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	The securities are held by Straight Lines Consultancy Pty Ltd as trustee for the Straight Lines Consultancy Trust. Mr Wright is a Director of Straight Lines Consultancy Pty Ltd and a Beneficiary of the Straight Lines Consultancy Trust.
Date of change	20 May 2014
No. of securities held prior to change	80,000 Ordinary Fully Paid Shares
Class	Ordinary Fully Paid Shares Listed Options (ASX:PAAO)
Number acquired	4,920,000 Ordinary Fully Paid Shares 375,000 Listed Options (ASX:PAAO)
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$940.00
No. of securities held after change	5,000,000 Ordinary Fully Paid Shares 375,000 Listed Options (ASX:PAAO)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market trade

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.